Lead Sponsor

Medical University of South Carolina

Collaborators

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

No

•SLE by ACR criteria (revised 1997)
•African American, participating in the SLE in Gullah Health (SLEIGH) Study
•Outpatient
•Stable disease with no BILAG A or B in any system for the past 4 weeks
•Stable prednisone (or equivalent corticosteroid) dose ≤ 20 mg/day for ≥ 4 weeks prior to study entry
•Baseline 25(OH)D concentration of \< 30 ng/ml
•Willingness to discontinue other vitamin D supplements and/or multivitamins containing vitamin D while participating in the study
•Age 18 - 85 years
•Ability to complete questionnaires in English
•Ability to give informed consent

•Presence of hypercalcemia (\>10.4 mg/dL), hypercalcuria (urinary calcium/creatinine ratio ≥ 0.8 mmol/mmol) or known primary hyperparathyroidism
•Liver disease (serum ALT, AST \>2x normal) or total serum bilirubin \>1.5x normal
•History of renal stones
•Current treatment with any dose of cyclophosphamide
•Dialysis or creatinine \> 2.5 mg/dL
•Pregnancy
•Current drug or alcohol abuse
•Anticipated poor compliance

Related studies

NCT07409181 · Systemic Lupus Erythematosus

NCT07043153 · Systemic Lupus Erythematosus Disease

NCT05869955 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, and more

NCT07558850 · Rheumatoid Arthritis, Dermatomyositis, and more

NCT07526350 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, and more

Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)